Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia
Ducastelle, S.; Adès, L.; Gardin, C.; Dombret, Hé.; Prébet, T.; Deconinck, E.; Rio, B.; Thomas, X.; Debotton, S.; Guerci, Aès.; Gratecos, N.; Stamatoullas, A.; Fegueux, N.; Dreyfus, Fçois.; Fenaux, P.; Wattel, E.
Haematologica 91(3): 373-376
2006
ISSN/ISBN: 0390-6078 PMID: 16531261 Document Number: 597988
We report on the outcomes of 53 patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia secondary to MDS, autografted in first complete remission. Five (9.4%) died from the procedure whereas hematological reconstitution occurred in all the remaining patients. Forty patients (75%) relapsed, with 87.5% of the relapses occurring within 2 years of the autologous transplant. With a median follow-up of 6.2 years, the median actuarial disease-free survival and overall survival were 8 and 17 months after autograft, respectively. Karyotype was the only prognostic factor for disease-free and overall survival. The eight survivors (15%), including two patients with unfavorable or intermediate karyotype, remained in first complete remission 50, to 119(+) months after transplantation and are probably cured.